Hoping To Smooth Relations With FDA, Sarepta Moves On From CEO Garabedian
This article was originally published in The Pink Sheet Daily
Executive Summary
Seeing Garabedian’s relationship with FDA as strained, Sarepta promotes Chief Medical Officer to interim CEO post in hopes of keeping eteplirsen on track for a mid-year NDA filing.
You may also be interested in...
Eteplirsen Approval Reflected FDA's Conflict On Accelerated Approval – Former Sarepta CEO
There is anxiety within the US agency over use of the pathway amid the prospect for confirmatory trials to fail, former CEO Garabedian says at FDA/CMS Summit.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.